HaTay Pharmaceutical JSC

HaTay Pharmaceutical JSC Debt

The Debt of HaTay Pharmaceutical JSC (DHT.VN) as of Nov 2, 2026 is 470.19 B VND. In the previous year, Debt was 503.70 B VND — a change of -6.65% (lower).

Debt

470.19 BVND

YoY

-6.65%

Last updated:

In 2024, HaTay Pharmaceutical JSC's total debt was 470.19 B VND, a -6.65% change from the 503.70 B VND total debt recorded in the previous year.

The HaTay Pharmaceutical JSC Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2017
227.66 B VND
Jan 1, 2018
195.33 B VND
Jan 1, 2019
162.15 B VND
Jan 1, 2020
204.18 B VND
Jan 1, 2021
289.43 B VND
Jan 1, 2022
336.84 B VND
Jan 1, 2023
503.70 B VND
Jan 1, 2024
470.19 B VND
The HaTay Pharmaceutical JSC Debt history
YEARDebtYoY
470.19 BVND-6.65%
503.70 BVND+49.54%
336.84 BVND+16.38%
289.43 BVND+41.75%
204.18 BVND+25.92%
162.15 BVND-16.99%
195.33 BVND-14.20%
227.66 BVND+34.87%
168.80 BVND+8.16%
156.07 BVND+19.89%
130.17 BVND—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

HaTay Pharmaceutical JSC Stock analysis

What does HaTay Pharmaceutical JSC do? Ha Tay Pharmaceutical JSC generates revenue through the manufacturing, import, and export of pharmaceuticals, cosmetics, and medical equipment. The company sells its products via wholesale and retail channels, targeting healthcare providers, pharmacies, and consumers. It also engages in the production and trading of cosmetic products, supplemental food, and laboratory chemicals, alongside medical equipment and supplies. The firm completed the acquisition of a 50.626% stake in Ha Tay Pharmaceutical and Medical Equipments Joint Stock Company in 2013, expanding its market presence in pharmaceuticals and medical equipment. The company operates in the pharmaceutical sector, serving healthcare institutions, retail pharmacies, and end consumers. Its revenue streams include the sale of drugs, cosmetics, medical equipment, and related supplies. Additional income comes from supermarket operations, real estate leasing, and vocational training services, though these are secondary to its core pharmaceutical business. Ha Tay Pharmaceutical JSC's primary customers are healthcare providers, pharmacies, and consumers purchasing pharmaceuticals, cosmetics, and medical equipment. The firm's product portfolio spans drugs, vaccines, cosmetic products, supplemental food, and laboratory chemicals, with a focus on manufacturing and trading. The acquisition of the 50.626% stake in Ha Tay Pharmaceutical and Medical Equipments Joint Stock Company has strengthened its position in the medical equipment market. HaTay Pharmaceutical JSC is one of the most popular companies on Eulerpool.

Debt Details

Understanding HaTay Pharmaceutical JSC's Debt Structure

HaTay Pharmaceutical JSC's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing HaTay Pharmaceutical JSC's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to HaTay Pharmaceutical JSC’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in HaTay Pharmaceutical JSC’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about HaTay Pharmaceutical JSC stock

Debt of HaTay Pharmaceutical JSC is 470.19 B VND in 2024.

Debt of HaTay Pharmaceutical JSC changed from 503.70 B VND to 470.19 B VND, representing a -6.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt HaTay Pharmaceutical JSC since 2006 – with annual values, charts, and detailed analysis.

Debt's VND is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's HaTay Pharmaceutical JSC historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — HaTay Pharmaceutical JSC

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — HaTay Pharmaceutical JSC